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ABSTRACT
Objective To evaluate the risk of upper gastrointestinal
complications (UGIC) associated with drug use in the
paediatric population.
Methods This study is part of a large Italian
prospective multicentre study. The study population
included children hospitalised for acute conditions
through the emergency departments of eight clinical
centres. Patients admitted for UGIC (defined as
endoscopically confirmed gastroduodenal lesions or
clinically defined haematemesis or melena) comprised
the case series; children hospitalised for neurological
disorders formed the control group. Information on drug
and vaccine exposure was collected through parental
interview during the children’s hospitalisation. Logistic
regression was used to estimate ORs for the occurrence
of UGIC associated with drug use adjusted for age,
clinical centre and concomitant use of any drug.
Results 486 children hospitalised for UGIC and 1930
for neurological disorders were enrolled between
November 1999 and November 2010. Drug use was
higher in cases than in controls (73% vs 54%;
p<0.001). UGICs were associated with the use of non-
steroidal anti-inflammatory drugs (NSAIDs) (adjusted OR
2.9, 95% CI 2.1 to 4.0), oral steroids (adjusted OR 2.9,
95% CI 1.7 to 4.8) and antibiotics (adjusted OR 2.3,
95% CI 1.8 to 3.1). The duration of use of these drug
categories was short (range 1–8 days). Paracetamol
showed a lower risk (adjusted OR 2.0, 95% CI 1.5 to
2.6) compared to ibuprofen (adjusted OR 3.7, 95% CI
2.3 to 5.9), although with partially overlapping CIs.
Conclusions NSAIDs, oral steroids and antibiotics,
even when administered for a short period, were
associated with an increased risk of UGIC.
INTRODUCTION
Mucosal damage to the gastrointestinal tract may
lead to a wide spectrum of disorders, from asymp-
tomatic minimal lesions, to severe, potentially fatal,
complications.1 Upper gastrointestinal complica-
tions (UGICs) such as bleeding are often associated
with drug use, especially non-steroidal anti-
inflammatory drugs (NSAIDs), oral steroids and
oral anticoagulants.2 3
NSAIDs inhibit the cyclooxygenase enzymes
catalysing the production of prostaglandins and
thromboxane, with consequent reduced release of
gastric mucus, inhibition of bicarbonate production
and alteration of local microcirculation.4 Steroids
can also enhance gastrin secretion and induce
parietal cell hyperplasia with increased acid
production.5
In adults, a small number of studies have specific-
ally examined the association between corticoster-
oids and gastrointestinal toxicity6–8 and there is an
extensive body of literature on gastrointestinal com-
plications related to drug consumption, but few
studies have focused on children.5 9–13
Since 1999 active surveillance of the role of
drugs and vaccines in the occurrence of specific
clinical conditions responsible for the hospitalisa-
tion of paediatric patients has been conducted in
Italy. This surveillance is useful for highlighting or
confirming adverse effects associated with drug and
vaccine use in children.14–17
In the present article we focus on the occurrence
of hospitalisation for UGIC in association with
drugs frequently used in the paediatric population,
with particular emphasis on antipyretics/analgesics,
steroids and antibiotics.
METHODS
Study population
The study population consists of all children admit-
ted through the emergency departments (ED) of
eight Italian paediatric hospitals in Genoa, Turin,
Padua, Florence, Rome (two hospitals), Naples and
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What is already known on this topic
▸ Gastrointestinal toxicity in association with
non-steroidal anti-inflammatory drugs (NSAIDs)
and corticosteroids in adults is well
documented.
▸ There are only a few studies describing the
association between gastrointestinal toxicity
and NSAID use in children.
What this study adds
▸ Our study confirms a threefold increased risk of
upper gastrointestinal complications (UGIC)
associated with either NSAID or oral
corticosteroid use.
▸ A twofold increased risk of UGIC was estimated
for paracetamol and antibiotics.
218 Bianciotto M, et al. Arch Dis Child 2013;98:218–221. doi:10.1136/archdischild-2012-302100
Original article
D
rug
therapy
Palermo between 1 November 1999 and 30 November 2010.
Children were enrolled regardless of drug and vaccine use, if
they had the following conditions: endoscopically confirmed
UGIC (or clinical haematemesis and melena); neurological disor-
ders; non-infectious muco-cutaneous diseases and vasculitis; or
thrombocytopenia (platelet count <100 000/ml). Children with
concomitant diagnoses of cancer or immunodeficiency and age
less than 1 month were excluded.
Information on the reason for hospital admission was derived
from the ED records, and the final diagnosis was retrieved from
the clinical records after discharge. UGIC cases comprise all
children whose reason for admission included haematemesis/
melena and children who had received an endoscopy during
hospitalisation and were discharged with a diagnosis of gastro-
duodenal lesion. The following conditions were defined as gas-
troduodenal lesions on endoscopy: gastric and/or duodenal
ulcer, and gastric and/or duodenal erosions (with or without
bleeding).
Parents were interviewed, using a structured questionnaire,
during the hospital admission of their child. All medicines admi-
nistered in the previous 3 weeks and all vaccines received in the
previous 12 weeks were noted. Information on drug use, includ-
ing indication, dose, duration of treatment, prescriber (physician
or self-medication) and other personal data (age, gender,
weight, height, chronic diseases, parents’ education) was also
collected.
Data analysis
ORs of clinically defined (haematemesis and melena) or endo-
scopically confirmed UGIC associated with drug use were esti-
mated according to a case–control study design. Drug exposure
to specific drugs or drug categories in children admitted with
UGIC (cases) was compared to exposure in children admitted
for neurological disorders (controls). This control group was
chosen because drug exposure in children hospitalised for
neurological disorders accurately reflects drug exposure in the
population from which UGIC cases were derived.
Pre-existing chronic diseases were divided into six categories:
allergies, gastrointestinal diseases (gastroesophageal reflux,
coeliac disease, ulcerative colitis), haematological disorders,
recurrent infections, neurological problems and birth defects.
Indications for drug use were classified into nine groups: allergy,
asthma, pain or headache, fever, gastrointestinal diseases, otitis,
upper respiratory tract infections (URTI), prophylaxis and other
indications. The use of oral steroids was categorised as appropri-
ate or not, according to the approved indications; we considered
as appropriate prescriptions for asthma and allergy, while all
prescriptions for other indications (eg, fever, cough, otitis, pha-
ryngitis) were classified as inappropriate.
Categorical variables, presented as numbers and percentages,
were compared using the χ² test, while continuous variables,
reported as median (range), were evaluated using the Mann–
Whitney U test. All tests were two sided and significance was set
at p<0.05.
To estimate the adjusted ORs and related 95% CIs, we used
the multivariate logistic regression model. ORs were adjusted
for age, clinical centre, calendar year, presence of chronic dis-
eases and concomitant use of any other drug. Year of inclusion
in the study and chronic diseases did not modify the estimates
and, thus, were not included in the final logistic model.
Statistical analysis was performed using SPSS V.17.0 (SPSS,
Chicago, Illinois, USA).
Organisation and ethics
The protocol of the study was approved by the ethics committee
of each clinical centre. Informed consent for the use of data for
research purposes was obtained before parents were inter-
viewed. The study was coordinated by the National Centre of
Epidemiology of the National Institute of Health.
RESULTS
A total of 486 children hospitalised for UGIC and 1930 for
neurological disorders were enrolled in the study. Of the children
hospitalised for UGIC, 324 (66.6%) were admitted for haema-
temesis, 31 (6.4%) for melena, and 29 (6.0%) for both haema-
temesis and melena. The remaining 102 children (21.0%) who
were admitted for symptoms compatible with gastroduodenal
lesions (other than haematemesis/melena), such as abdominal
pain and vomiting, underwent endoscopy during hospitalisation
and were discharged with a diagnosis of UGIC. An endoscopy
was performed in 248 (51%) of the 486 UGIC cases.
The most frequent diagnoses in the 1930 children included in
the control group were afebrile convulsions (822, 43%), distur-
bances of consciousness (such as syncope, faintness, dizziness,
somnolence) (530, 27%), peripheral neuropathy (78, 4%) and
extrapyramidal symptoms (65, 3%).
The majority of cases (302 children, 62.1%) were admitted to
Santobono Hospital (Naples). The main characteristics of cases
and controls are summarised in table 1. Males were equally
represented in both groups, and cases were 5 months younger
than controls (p=0.01). However, age did not have a confound-
ing effect when taken into account in the logistic model.
Seventy-five of the 486 cases (15.4%) had concomitant chronic
diseases versus 265 of the 1930 controls (13.7%) (p=0.37).
Chronic gastrointestinal diseases were uncommon, although
more frequent in cases than in controls (2.5% vs 1.1%;
p=0.06). The presence of such conditions was an independent
Table 1 Characteristics of cases (upper gastrointestinal
complications) and controls (neurological disorders)
Cases
(N=486) %
Controls
(N=1930) % p Value
Median age, months
(25th–75th percentile)
41 (15–71) 46 (11–115) 0.01
Male 274 56.4 1002 51.9 0.08
Median LoS, days
(25th–75th percentile)
3 (2–5) 3 (2–6) 0.69
Chronic diseases 75 15.4 265 13.7 0.37
Allergy 47 9.7 168 8.7 0.98
Gastrointestinal disease 12 2.5 21 1.1 0.06
Haematological disorders 4 0.8 7 0.4 0.42
Recurrent infections 3 0.6 12 0.6 0.90
Neurological problems 8 1.6 40 2.1 0.43
Birth defects 10 2.1 41 2.1 0.78
Drug exposure
(at least one)
353 72.6 1042 54.0 <0.001
Indication for use of drugs*
URTI 141 39.9 259 24.9 <0.001
Fever 56 15.9 97 9.3 <0.001
Asthma 13 3.7 15 1.4 0.001
Allergy – – 19 1.8
*The percentage was calculated on drug exposure.
LoS, length of stay; URTI, upper respiratory tract infection.
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risk factor for UGIC manifestations with an adjusted OR of
2.3 (95% CI 1.1 to 4.9). However, after adjustment for the per-
sonal history of pre-existing gastrointestinal diseases, no con-
founding effect was found on the estimates. The number of
children who had received at least one drug within the 3 weeks
preceding the hospital admission was 353 among cases and
1042 among controls (73% vs 54%; p<0.001). The mean
number of drugs per child was 1.7 among cases and 1.1 among
controls (p<0.001). Approximately 17% of these drugs were
consumed without medical advice in both groups. The drugs
reported in the personal history were those most frequently pre-
scribed in the paediatric population in Italy, that is, antibiotics,
paracetamol, NSAIDs and steroids.
Duration of use was quite short and similar for all study
drugs. The median duration for NSAID administration was
3 days in cases and 2 days in controls (p=0.41). One child
(4 years old) admitted with haematemesis had been treated for
80 days with indomethacin and ibuprofen for arthritis. The
median duration of use for steroids was 3 days in cases and
4 days in controls (p=0.16). The indication was reported in 79
of the 87 steroid users (91%); in 17 children (21.5%) it was an
approved indication (eg, asthma, urticaria).
An increased risk of UGIC was found for the use of NSAIDs,
paracetamol, corticosteroids and antibiotics. The adjusted OR
among NSAID users was 2.9 (95% CI 2.1 to 4.0). The risk esti-
mates of individual NSAIDs and paracetamol presented largely
overlapping CIs (table 2).
On the basis of the number of children who visited the ED of
the participating centres in the year 2010, we calculate that
around 2.1 million children were treated in the participating
EDs during the study period. Thus, we can roughly estimate
that during the study period around 2.4 per 10 000 children
with ED visits were admitted for UGIC.
DISCUSSION
In this article we provided evidence of an increased risk of
UGICs associated with drug use in the paediatric population.
The proportion of children who had received at least one drug
in the 3 weeks preceding hospital admission was higher among
cases than among controls. Significantly increased risks were esti-
mated for NSAIDs, steroids and antibiotics. In agreement with
our findings, an increased risk for NSAIDs was also observed in a
case–crossover study of 177 children with gastrointestinal bleed-
ing.9 The adjusted OR for NSAIDs reached 8.2 (95% CI 2.6 to
26.0), with one third of cases attributable to exposure to NSAIDs
administered at analgesic or antipyretic doses.9 However, as
underlined by the authors, the study has several limitations and
the estimated risks appear higher than those observed in adults,2
since the findings may have been influenced by the limited
dataset and a recall bias could not be excluded.9
Among NSAIDs, ibuprofen was the most commonly used
drug. Although ibuprofen is safe in most children,18 the associ-
ation between gastrointestinal bleeding and ibuprofen use is well
known in both adults2 and children.10 We estimated an
increased risk of UGIC associated with ibuprofen (adjusted OR
3.7, 95% CI 2.3 to 5.9). It has to be noted that our estimate is
included in the large CI of the case–crossover study9 and over-
laps with findings reported in adults (a twofold to fourfold
increase in relative risks).2 It is assumed that gastrointestinal
bleeding is associated with chronic use of NSAIDs.19 However,
in our study the mean duration of ibuprofen use in cases was
4 days, so UGIC may occur even during a short course therapy.
We confirm the lower level of gastrotoxicity, in comparison with
NSAIDs, of paracetamol, the most widely used drug in the
paediatric population in Italy.
Steroid prescribing was off-label in a large proportion of cases
and was mostly used for URTI or fever. This finding underlines
the need for educational programmes in Italy to promote the
correct use of steroids in children. Notably, the association with
UGIC was limited to oral steroid use as no increased risk was
observed among users of inhaled steroids.
Although poorly documented in the literature, gastrointestinal
adverse reactions, featuring diarrhoea, nausea and abdominal
pain, related to antibiotic administration, are usually mild and
reversible with treatment cessation.20 21 There are very few data
on the upper gastrointestinal toxicity of antibiotics. Immune
-mediated thrombocytopenia is often implicated in bleeding
mechanisms associated with antibiotics, in particular
β-lactams.22 In our study, however, children hospitalised for
UGIC did not have a concomitant diagnosis of thrombocyto-
penia. The reason for an increased risk of UGIC among anti-
biotic users, after taking into account the effect of age and
concomitant use of other drugs, remains unclear.11 22 23
Our study has several potential limitations. Cases were signifi-
cantly younger than controls; however, the risk estimates did
not change after age was taken into account in the logistic
model. An endoscopy was performed only in half of the chil-
dren diagnosed with UGIC; however, all cases without endo-
scopic confirmation had haematemesis or melena at admission.
The risk estimates did not change when the analysis was
restricted to children who underwent endoscopy.
As in other case–control studies, the possibility of a recall bias
cannot be excluded. However, such a bias cannot explain the
observed risk estimates since the ascertainment of exposure was
based on the same procedure in cases and controls (interviewing
Table 2 ORs and CIs of upper gastrointestinal complications in
association with drugs*
Drugs
Cases
(N=486)
Controls
(N=1930) Adjusted OR†
(95% CI)n n
Antibiotics 135 242 2.3 (1.8 to 3.1)
Amoxicillin+clavulanic
acid
44 77 2.3 (1.5 to 3.5)
Claritromicin 17 30 2.0 (1.0 to 3.8)
Amoxicillin 16 30 1.8 (0.9 to 3.4)
Cefaclor 14 24 1.7 (0.8 to 3.5)
Steroids 87 140 1.9 (1.4 to 2.7)
Oral steroids 39 30 2.9 (1.7 to 4.8)
Inhaled steroids 24 81 1.0 (0.6 to 1.7)
Oral+inhaled steroids 20 18 3.0 (1.5 to 5.9)
NSAIDs 81 121 2.9 (2.1 to 4.0)
Ibuprofen 40 51 3.7 (2.3 to 5.9)
Niflumic acid 14 23 1.6 (0.8 to 3.2)
Ketoprofen 12 23 2.6 (1.2 to 5.6)
Paracetamol 119 294 2.0 (1.5 to 2.6)
Paracetamol
+ibuprofen
16 21 3.1 (1.5 to 6.2)
Aspirin 6 12 2.5 (0.9 to 7.4)
Other drugs 186 746 0.8 (0.7 to 1.1)
Total drug use 353 1042
*All drugs with at least 10 exposed in the control group.
†Adjusted for age, clinical centre and concomitant use of other drugs.
NSAIDs, non-steroidal anti-inflammatory drugs; UGIC, upper gastrointestinal
complications.
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parents during their child’s hospitalisation). Children hospita-
lised for neurological problems are a suitable control group for
patients with UGICs. Both cases and controls were admitted
through EDs for an acute condition and, consequently, drug use
preceding symptoms causing hospitalisation should not differ
between cases and controls.
Pre-existing chronic conditions were unlikely to have influ-
enced the results, since the proportions of children with chronic
conditions were similar in the two groups. However, the small
sample size of some subgroups may have limited our ability to
draw definitive conclusions regarding some specific drugs.
Our study indicates that UGIC is a rare event (486 children
hospitalised in just over 11 years). Although, given the case–
control design, we could not calculate incidence, the number of
UGIC patients admitted through EDs can be roughly estimated
as 2.4 per 10 000 children with ED visits. Published incidence
data are limited to the paediatric intensive care unit popula-
tion,24 which cannot be compared with children who develop
an UGIC as outpatients. Our study suggests that the absolute
risk of UGIC is low, nevertheless it remains to be determined if
all prescriptions were really necessary. The appropriate use of
drugs in children should be promoted in order to prevent the
occurrence of serious adverse events.
The Italian Multicenter Study Group for Drug and Vaccine Safety in
Children The Italian Multicenter Study Group for Drug and Vaccine Safety in
Children: Francesca Menniti-Ippolito, Roberto Da Cas, Luciano Sagliocca, Giuseppe
Traversa (National Center for Epidemiology, National Institute of Health, Rome);
Fernanda Ferrazin, Carmela Santuccio, Loriana Tartaglia, Francesco Trotta (Italian
Medicines Agency, Rome); Pasquale Di Pietro, Salvatore Renna, Rossella Rossi,
Bianca Domenichini, Stefania Gamba, Francesco Trovato (Giannina Gaslini Paediatric
Hospital, Genoa); Pier-Angelo Tovo, Manuela Bianciotto, Carmelina Calitri, Clara
Gabiano, Irene Raffaldi, Antonio Urbino (Regina Margherita Paediatric Hospital,
Turin); Liviana Da Dalt, Valentina Favero, Laura Giordano, Maura Baraldi, Federica
Bertuola, Eleonora Lorenzon, Francesca Parata, Giorgio Perilongo, Silvia Vendramin
(Department of Paediatrics, University of Padua); Monica Frassineti, Anna Maria
Calvani, Elena Chiappini, Maurizio De Martino, Claudia Fancelli, Francesco Mannelli,
Rachele Mazzantini, Sara Sollai, Elisabetta Venturini (Anna Meyer Children’s
University Hospital, Florence); Nicola Pirozzi, Umberto Raucci, Antonino Reale,
Rossella Rossi (Emergency Department, Bambino Gesù Children’s Hospital, Rome);
Nadia Mores, Giulia Bersani, Alessia De Nisco, Antonio Chiaretti, Riccardo Riccardi,
Costantino Romagnoli (Pharmacology and Paediatrics and Developmental
Neuroscience, Università Cattolica S. Cuore, Rome); Vincenzo Tipo, Michele Dinardo,
Teresa Pisapia (Santobono Paediatric Hospital, Naples); Annalisa Capuano, Elisabetta
Parretta, Concita Rafaniello (Department of Experimental Medicine, Section of
Pharmacology ‘L. Donatelli’, Second University of Naples, Naples); Fortunata Fucà,
Eleonora Di Rosa (Giovanni Di Cristina Paediatric Hospital, Palermo).
Funding This study was funded by the Italian Medicines Agency (AIFA) (Fasc. ISS-T7H).
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Carvalho ED, Nita MH, Paiva LM, et al. Gastrointestinal bleeding. J Pediatr 2000;1:
S135–46.
2 Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal
complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids,
acetaminophen, and combination of these agents. Arthritis Res 2001;3:98–101.
3 Pirmohamed M, James S, Meakin S, et al. Adverse drug reaction as cause of
admission to hospital: prospective analysis of 18820 patients. BMJ
2004;329:15–19.
4 Al Mofleh IA, Al Rashed RS. Nonsteroidal antinflammatory drug-induced
gastrointestinal injuries and related adverse reactions: epidemiology, pathogenesis
and management. Saudi J Gastroenterol 2007;13:107–13.
5 Luo JC, Chang FY, Chen TS, et al. Gastric mucosal injury in systemic lupus
erithematosus patients receiving methylprednisolone therapy. Br J Clin Pharmacol
2009;68:252–9.
6 Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease:
role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735–40.
7 Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal
complications. Am J Epidemiol 2001;153:1089–93.
8 Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy
and peptic-ulcer disease. NEJM 1983;309:21–4.
9 Grimaldi-Bensouda L, Abenhaim L, Michaud L, et al. Clinical features and risk
factors for upper gastrointestinal bleeding in children: a case-crossover study. Eur J
Clin Pharmacol 2010;66:831–7.
10 Autret-Leca E, Bensouda-Grimaldi L, Maurage C, et al. Upper gastrointestinal
complications associated with NSAIDs in children. Therapie 2007;62:173–6.
11 Ozen IO, Moralioglu S, Karabulut R, et al. Cefoperazone induced gastro-intestinal
haemorrhage. A case report. Acta Chir Belg 2008;108:777–8.
12 Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide
antibacterials in paediatric patients. Drug Saf 1999;20:25–41.
13 Klein JO. History of macrolide use in pediatrics. Pediatr Infect Dis J
1997;16:427–31.
14 Menniti-Ippolito F, Sagliocca L, Da Cas R, et al. Niflumic acid and cutaneous
reactions in children. Arch Dis Child 2001;84:430–1.
15 Menniti-Ippolito F, Traversa G, Da Cas R, et al. Extrapyramidal reactions in children
treated with metoclopramide. Ital J Pediatr 2004;30:49–52.
16 Bertuola F, Morando C, Menniti-Ippolito F, et al. Association between drug and
vaccine use and acute immune thrombocytopenia in childhood. A case control study
in Italy. Drug Saf 2010;33:65–72.
17 Menniti-Ippolito F, Da Cas R, Sagliocca L, et al. Effectiveness and safety of the
A-H1N1 vaccine in children: a hospital-based case-control study. BMJ Open 2011;2:
e000167.
18 Southey ER, Soares-Weiser K, Kleijnen J, et al. Systematic review and meta-analysis
of the clinical safety and tolerability of ibuprofen compared with paracetamol in
paediatric pain and fever. Curr Med Res Opin 2009;25:2207–2.
19 Berezin SH, Bostwick HE, Halata MS, et al. Gastrointestinal bleeding in children
following ingestion of low dose ibuprofen. J Pediatr Gastroenterol Nutr
2007;44:506–8.
20 Rouveix B. Antibiotic safety assessment. Int J Antimicrob Agents 2003;21:215–21.
21 Lode H. Safety and tolerability of commonly prescribed oral antibiotics for the
treatment of respiratory tract infections. Am J Med 2010;123:S26–38.
22 Shevchuk YM, Conly JM. Antibiotics-associated hypoprothrombinemia: a review of
prospective studies, 1966-1988. Rev Infect Dis 1990;12:1109–26.
23 Schetag JJ, Welage LS, Grasela TH, et al. Determinants of antibiotic-associated
hypoprothrombinemia. Pharmacotherapy 1987;7:80–6.
24 Victor L, Fox MD. Gastrointestinal bleeding in infancy and childhood. Gastroenterol
Clin North Am 2000;29:37–66.
Bianciotto M, et al. Arch Dis Child 2013;98:218–221. doi:10.1136/archdischild-2012-302100 221
Original article
